Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
BioRestorative Therapies's Enterprise Value for the quarter that ended in Mar. 2026 was €2.55 Mil.
BioRestorative Therapies's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-12.22 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioRestorative Therapies EV-to-EBIT Related Terms
BioRestorative Therapies EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:9OF vs LIMN, BOLT, TRAW: EV-to-EBIT Comparison
For the Biotechnology subindustry, BioRestorative Therapies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioRestorative Therapies EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where BioRestorative Therapies's EV-to-EBIT falls into.
BioRestorative Therapies's current Enterprise Value is €-5.49 Mil.
BioRestorative Therapies's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-12.22 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioRestorative Therapies (FRA:9OF) has a EV-to-EBIT of 0.45 as of Jul. 29, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on BioRestorative Therapies and its competitors. According to the industry distribution chart, BioRestorative Therapies ranks #59 out of 381 companies in the Biotechnology industry, placing it in the top 15.5%.
Is BioRestorative Therapies' EV-to-EBIT too high?
BioRestorative Therapies' current EV-to-EBIT is 0.45. The Biotechnology industry median EV-to-EBIT is 12.81. BioRestorative Therapies' value of 0.45 is 96.5% below this industry median. Based on the distribution chart, BioRestorative Therapies ranks #59 out of 381 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioRestorative Therapies has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioRestorative Therapies' EV-to-EBIT compare to LIMN and BOLT?
According to the Biotechnology industry distribution chart, BioRestorative Therapies ranks #59 out of 381 companies for EV-to-EBIT. This places BioRestorative Therapies in the top 16% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 12.81. BioRestorative Therapies' value of 0.45 is 96.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.81, based on 381 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioRestorative Therapies's current EV-to-EBIT of 0.45 is 96.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on BioRestorative Therapies and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioRestorative Therapies's current EV-to-EBIT is 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRestorative Therapies stock overvalued right now?
Based on GuruFocus' analysis, BioRestorative Therapies (FRA:9OF) is currently considered Possible Value Trap. The stock's GF Value™ is €1.35, compared to a current price of €0.24 — trading 82.4% below its estimated fair value. The current EV-to-EBIT is 0.45 and 96.5% below the Biotechnology industry median of 12.81. BioRestorative Therapies' overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For BioRestorative Therapies (FRA:9OF), the current EV-to-EBIT is 0.45 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioRestorative Therapies (FRA:9OF) Overvalued in 2026?
Based on GuruFocus' analysis, BioRestorative Therapies stock appears to be undervalued.
The current stock price of €0.24 is trading 82.4% below its estimated GF Value™ of €1.35.
GuruFocus considers BioRestorative Therapies to be Possible Value Trap.
Key valuation signals for FRA:9OF:
EV-to-EBIT: 0.45
GF Value™: €1.35 vs. price of €0.24 (82.4% below fair value)
Industry Position: 96.5% below the Biotechnology median (#59 of 381)
No single metric tells the full story. See the FRA:9OF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
55GF Score
Get the complete analysis for FRA:9OF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9OF has been successfully added to your 
